Cargando…
MET基因改变的非小细胞肺癌靶向治疗耐药机制及治疗策略
Mesenchymal to epithelial transition factor (MET) gene alterations involve in the proliferation, invasion, and metastasis of non-small cell lung cancer. MET-tyrosine kinase inhibitors (TKIs) have been approved to treat non-small cell lung cancer with MET alterations, and resistance to these TKIs is...
Autores principales: | LI, Shuzhan, ZHANG, Xinwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial board of Chinese Journal of Lung Cancer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600752/ https://www.ncbi.nlm.nih.gov/pubmed/37985154 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.33 |
Ejemplares similares
-
表皮生长因子受体基因突变非小细胞肺癌的靶向治疗及其耐药机制
Publicado: (2022) -
肺癌免疫治疗耐药机制及应对策略
Publicado: (2021) -
ALK阳性非小细胞肺癌靶向治疗耐药机制及预后标志物的研究进展
Publicado: (2020) -
非小细胞肺癌分子靶向治疗中EGFR-TKI的耐药机制研究进展
Publicado: (2012) -
奥希替尼在非小细胞肺癌靶向治疗中的获得性耐药机制
Publicado: (2020)